Weekly Report on China's Health Industry: Metrics Technologies Clears HKEX Hearing with $1B+ Valuation; BYD’s Third-Largest Shareholder Nears Another Medical IPO

Valuation exceeds $1 billion, JetTech passes Hong Kong listing hearing

JiTai Technology Accelerates HKEX Listing Process, Submitted Application Confidentially on February 12, Went Public on March 25, Passed Hearing on April 19, and is Expected to be Listed on HKEX Soon. As an Innovation Leader in AI Nanomaterials, JiTai Technology is Committed to the Delivery and Application of Payloads Across All Life Forms. It Was Co-founded by Dr. Lai in 2020. In July 2025, JiTai Technology Completed its Series C Financing Round of 350 Million Yuan, with a Post-money Valuation of 1.049 Billion US Dollars, Accumulating Over 2 Billion Yuan in Total Financing. (Source: Arterial Network)

BYD's Third Largest Shareholder to Harvest Another Medical IPO

On April 15, 2026, Annoroad Gene Technology (Beijing) Co., Ltd. submitted its third application for listing on the Hong Kong Stock Exchange Main Board, with joint sponsors being CCB International and Guotai Junan International. From the first filing in March 2025, which expired in September, to the second filing in September of the same year and another expiration in March 2026, this NIPT (non-invasive prenatal genetic testing) leading company, invested in by one of BYD's co-founders, Xia Zuozheng, is knocking on the door of the capital market for the third time. Compared to the previous two filings, Annoroad’s corporate positioning has quietly shifted—from emphasizing "integrated life science sequencing solutions" to "focusing on clinical IVD and growth driven by marketing as the NIPT leader," while adding new pipelines such as Alzheimer's disease (AD) testing in an attempt to break the reliance on a single product. (Source: Arterial Network)

1.6 Million Yuan! Fujian Medical University Plans to Transfer a Surgical Retractor Device

Recently, the First Affiliated Hospital of Fujian Medical University plans to transfer the patent "A Telescopic Surgical Retractor." This transaction will adopt a patent assignment model, with a proposed transfer amount of 160,000 yuan. The assignor is the First Affiliated Hospital of Fujian Medical University, and the assignee is Hangzhou Qinglang Technology Co., Ltd. The inventors of this patent are Lin Jianbo and his team. (Source: Vbdata.cn)

CareRay Digital Medical Technology Co., Ltd. Announces Plan to Acquire Control of Medlead Intelligent Technology (Wuxi) with Cash

On the evening of April 14, CareRay Digital Medical Technology Co., Ltd. announced a proposal to acquire a controlling stake in Meddle Intelligent Technology (Wuxi) with cash. The shareholding ratio will reach 50.7355% to 51%, with an overall valuation of 750 million yuan. This move will help CareRay quickly enter the ultrasound AI track and achieve an integrated transformation of "hardware + AI software." Meddle Intelligent focuses on the research, development, and transformation of artificial intelligence medical big data algorithms and holds a Class III certificate for thyroid nodule ultrasound AI, with a diagnostic accuracy rate of 96%. Currently, AI healthcare is entering a period of consolidation, with mergers and acquisitions, financing, and the entry of major players accelerating. (Source: Sina Finance)

FemtoMarch Medical Completes Nearly 100 Million Yuan in Angel Round Financing

Recently, Shenzhen FemtoMarch Medical Technology Co., Ltd. (hereinafter referred to as "FemtoMarch Medical") announced the completion of an angel round of financing worth nearly 100 million yuan. This round of financing was led by Vivo Capital, with follow-up investments from Zero2IPO Group, Zero2IPO University Student Entrepreneurship Fund, and Yingtong Lianchuang. The funds will be used for product technology iteration and upgrades, clinical trials, animal experiments, etc. (Source: Vbdata.cn)

Donao Medical Successfully Completes Seed Round Financing

Recently, Dongnao Medical Technology (Tianjin) Co., Ltd. ("Dongnao Medical" for short) announced the completion of its seed round financing, which was exclusively invested by Tianjin Heying Haihe Brain-Computer Fund. Dongnao Medical focuses on the innovation of non-invasive brain function monitoring technology to accelerate the clinical application of cutting-edge technologies such as brain-computer interfaces and artificial intelligence, using technological innovation to provide precise support for brain health management. This investment from Tianjin Heying Haihe Brain-Computer Interface Fund not only recognizes Dongnao Medical's technological leadership but also marks its strategic elevation from a "brain function monitoring innovator" to a "co-builder of the brain-computer interface ecosystem." (Source: Arterial Network)

Luofang Bio Receives Tens of Millions in Seed Funding

China's First Biotech Company Focused on Innovative Polymer Drug R&D and Translation —— Luofang Bio Completes Multi-Million Yuan Seed Round Financing, Led by Origin Capital with Participation from FemtoMarch Medical Innovation Seed Fund. The proceeds will be mainly used to advance preclinical research and IND application for the first polymer drug pipeline targeting cardiovascular calcification, a chronic disease, while simultaneously expanding multiple chronic disease-related polymer drug projects into clinical translation. (Source: Arterial Network)

Ruihe Health Completes Seed Round Financing

Anti-Medical AI Company ReHealth AI Has Completed RMB 4 Million Seed Round Financing, with a Post-Investment Valuation of RMB 25 Million; the Investor Remains Undisclosed. In Addition to Providing Financial Support, the Investor Offers In-Depth Collaboration at the Business Level. This Round of Funding Will Be Used for Small-Scale Clinical Retrospective Testing, Class II Medical Device Software Application, Algorithm and Model Registration, as Well as Engineering Implementation of the Complete Closed Loop of Prediction-Intervention-PSM Attribution-Settlement Validation. (Source: Arterial Network)

NMPA Issues 87 Notifications, Several Key Products Not Approved

China's National Medical Products Administration released the drug notification delivery information on April 14, 2026, with this batch including 87 acceptance numbers receiving notifications. Among them, Qilu Pharmaceutical challenged the rare disease drug nusinersen sodium injection for generic production and received a notification; Zhejiang Shengzhaoyao challenged the failed attempt of leuprolide acetate microspheres for injection, and currently, only the original research company Takeda and Shanghai Lizhu hold the registration numbers for this variety; four companies, including Kelun, received four consecutive notifications related to bilastine products; Humanwell Pharma received a notification for its dexmethylphenidate hydrochloride sustained-release capsules, previously its two acceptance numbers were either voluntarily withdrawn, but a few days ago, it resubmitted the listing application; Daiichi Sankyo’s pixantrone hydrochloride capsules received a notification, which is the first and only approved drug for treating symptomatic tenosynovial giant cell tumor (TGCT). The complete certificate information source is from Yaoke headlines. (Source: Sina.com)